{
    "root": "c6e20031-cb11-4a7d-80d0-5dceee919da0",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "PADCEV",
        "suffix": {
            "text": "EJFV"
        }
    },
    "value": "20250228",
    "ingredients": [
        {
            "name": "ENFORTUMAB VEDOTIN",
            "code": "DLE8519RWM"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E"
        },
        {
            "name": "HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE",
            "code": "X573657P6P"
        },
        {
            "name": "TREHALOSE DIHYDRATE",
            "code": "7YIN7J07X4"
        },
        {
            "name": "POLYSORBATE 20",
            "code": "7T1F30V5YH"
        }
    ],
    "indications": "padcev\u00ae , combination pembrolizumab , indicated treatment adult patients locally advanced metastatic urothelial cancer ( muc ) . padcev , single agent , indicated treatment adult patients locally advanced muc : \u2022have previously received programmed death receptor-1 ( pd-1 ) programmed death-ligand 1 ( pd-l1 ) inhibitor platinum-containing chemotherapy , \u2022are ineligible cisplatin-containing chemotherapy previously received one prior lines therapy .",
    "contraindications": "\u2022 intravenous infusion . administer padcev intravenous push bolus . mix , administer infusion , medicinal products . ( 2.3 ) \u2022 recommended dose padcev combination pembrolizumab 1.25 mg/kg ( maximum dose 125 mg ) given intravenous infusion 30 minutes days 1 8 21-day cycle disease progression unacceptable toxicity . ( 2.1 ) \u2022 recommended dose padcev single agent 1.25 mg/kg ( maximum dose 125 mg ) given intravenous infusion 30 minutes days 1 , 8 15 28-day cycle disease progression unacceptable toxicity . ( 2.1 ) \u2022 avoid patients moderate severe hepatic impairment ( 8.6 )",
    "warningsAndPrecautions": "supplied padcev ( enfortumab vedotin-ejfv ) 20 mg 30 mg supplied sterile , preservative-free , white off-white lyophilized powder single-dose vials . padcev vials available following packages : \u2022carton one 20 mg single-dose vial ( ndc 51144-020-01 ) \u2022carton one 30 mg single-dose vial ( ndc 51144-030-01 ) storage store padcev vials refrigerated 2\u00bac 8\u00bac ( 36\u00baf 46\u00baf ) original carton . freeze . shake . special handling padcev hazardous . follow applicable special handling disposal procedures.1",
    "adverseReactions": "none .",
    "indications_original": "PADCEV\u00ae, in combination with pembrolizumab, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC).\n                  PADCEV, as a single agent, is indicated for the treatment of adult patients with locally advanced or mUC who:\n                  \n                     \n                        \u2022have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or\n                     \n                        \u2022are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.",
    "contraindications_original": "\u2022 For intravenous infusion only. Do not administer PADCEV as an intravenous push or bolus. Do not mix with, or administer as an infusion with, other medicinal products. ( 2.3 ) \u2022 The recommended dose of PADCEV in combination with pembrolizumab is 1.25\u00a0mg/kg (up to a maximum dose of 125 mg) given as an intravenous infusion over 30 minutes on Days 1 and 8 of a 21-day cycle until disease progression or unacceptable toxicity. ( 2.1 ) \u2022 The recommended dose of PADCEV as a single agent is 1.25 mg/kg (up to a maximum dose of 125 mg) given as an intravenous infusion over 30 minutes on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity. ( 2.1 ) \u2022 Avoid use in patients with moderate or severe hepatic impairment ( 8.6 )",
    "warningsAndPrecautions_original": "How Supplied \n                  \n                  PADCEV (enfortumab vedotin-ejfv) 20 mg and 30 mg are supplied as a sterile, preservative-free, white to off-white lyophilized powder in single-dose vials. PADCEV vials are available in the following packages:\n                  \n                     \n                        \u2022Carton of one 20 mg single-dose vial (NDC 51144-020-01)\n                     \n                        \u2022Carton of one 30 mg single-dose vial (NDC 51144-030-01)\n                  \n                  \n                     Storage\n                  \n                  Store PADCEV vials refrigerated at 2\u00baC to 8\u00baC (36\u00baF to 46\u00baF) in the original carton. Do not freeze. Do not shake.\n                  \n                     Special Handling\n                  \n                  PADCEV is a hazardous drug. Follow applicable special handling and disposal procedures.1",
    "adverseReactions_original": "None."
}